Physician profile
Brook Whitaker
NPI 1043783673
$9,353.49
in general payments reported to CMS, 2019-2025
50 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what 96% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,444 · 2022: $2,454 · 2023: $2,546 · 2024: $671 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,456.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,473.08 | 2021-2025 | |
| Novo Nordisk INC | $1,023.91 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $885.00 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $838.73 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $695.64 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $526.62 | 2023-2025 | |
| Amgen INC. | $448.92 | 2021-2024 | Evenity, Prolia, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $347.56 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.20 | 2021-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $228.40 | 2021 | |
| Pfizer INC. | $212.60 | 2021-2025 | |
| Eisai INC. | $198.60 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $178.94 | 2021-2023 | |
| Axsome Therapeutics, INC. | $170.27 | 2023-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $162.93 | 2021-2023 | Verquvo, Belsomra, Steglatro |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brook Whitaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.